Wu Xuanxuan, Gou Pan, Fang Chencheng, Zhou Yudong, Li Lusheng, Zhai Xuan, Liang Ping
Department of Neurosurgery, Children's Hospital of Chongqing Medical University National Clinical Research Center for Child Health and Disorders Ministry of Education Key Laboratory of Child Development and Disorders Chongqing Key Laboratory of Pediatrics Chongqing China.
Pediatr Discov. 2024 Jul 31;2(3):e81. doi: 10.1002/pdi3.81. eCollection 2024 Sep.
The crucial role of ribonucleotide reductase M2 (RRM2) enzyme in cancer occurrence and progression has been well-established, but its specific function and significance in medulloblastoma (MB) remains largely unknown. First, we conducted a bioinformatics analysis of public genomic databases and observed highly expressed RRM2 in MB and an association of high RRM2 expression with adverse outcomes. In addition, by collecting clinical MB specimens for polymerase chain reaction (PCR), western blotting (WB), and immunohistochemistry (IHC), RRM2 was confirmed to be highly expressed in tumor tissues. Furthermore, immunohistochemical analysis linked adverse prognosis to high RRM2 expression. Moreover, knocking down RRM2 significantly inhibited MB cell proliferation, migration, and invasion in vitro. This report is the first to demonstrate the oncogenic role of RRM2 in MB, associated with adverse patient outcomes. Knocking down RRM2 contributes to weakened proliferating, migrating, and invading potentials of MB cells. RRM2 is expected to be a novel prognostic biomarker and therapeutic target for MB.
核糖核苷酸还原酶M2（RRM2）在癌症发生和发展中的关键作用已得到充分证实，但其在髓母细胞瘤（MB）中的具体功能和意义仍 largely未知。首先，我们对公共基因组数据库进行了生物信息学分析，观察到RRM2在MB中高表达，且RRM2高表达与不良预后相关。此外，通过收集临床MB标本进行聚合酶链反应（PCR）、蛋白质免疫印迹法（WB）和免疫组织化学（IHC），证实RRM2在肿瘤组织中高表达。此外，免疫组织化学分析将不良预后与RRM2高表达联系起来。此外，敲低RRM2显著抑制了MB细胞在体外的增殖、迁移和侵袭。本报告首次证明了RRM2在MB中的致癌作用，与患者不良预后相关。敲低RRM2有助于削弱MB细胞的增殖、迁移和侵袭潜能。RRM2有望成为MB的一种新型预后生物标志物和治疗靶点。
